Rapport Therapeutics (NASDAQ:RAPP) Shares Down 7.7% – Should You Sell?

Rapport Therapeutics, Inc. (NASDAQ:RAPP) dropped 7.7% during trading on Thursday . The company traded as low as $28.55 and last traded at $28.1770. Approximately 66,910 shares traded hands during trading, a decline of 80% from the average daily volume of 339,985 shares. The stock had previously closed at $30.54.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term EPS forecasts for RAPP (Q1–Q4 2026 and FY2026) and lifted FY2027/FY2028 estimates, while maintaining a “Buy” rating and a $40 price target — supportive for upside if clinical or commercial progress continues. Read More.
• Neutral Sentiment: HC Wainwright posted a FY2030 EPS projection (longer‑range modeling) that is not an immediate driver of near‑term price action but signals analyst coverage continues to model multi‑year outcomes. Read More.
• Neutral Sentiment: A Globenewswire filing posted preparatory materials for a March 27 corporate meeting (annual report/AGM materials). This appears administrative and unlikely to be material to near‑term stock moves. Read More.
• Negative Sentiment: RAPP reported an earnings miss (reported March 10), which triggered a gap‑down and sell‑off; one article highlights the immediate downward reaction and higher trading volume as investors reprice near‑term performance risk. Read More.
• Negative Sentiment: Although many near‑term estimates were raised, HC Wainwright materially worsened its FY2029 EPS forecast (larger loss), which increases uncertainty about later‑stage profitability and may weigh on longer‑dated investor expectations. Read More.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RAPP shares. Wells Fargo & Company boosted their target price on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a research note on Wednesday. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday. BTIG Research upped their price objective on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rapport Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Rapport Therapeutics Stock Performance

The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -9.73 and a beta of 1.51. The company has a 50 day moving average price of $28.10 and a two-hundred day moving average price of $26.99.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). On average, equities analysts expect that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.34, for a total value of $171,140.22. Following the sale, the chief executive officer owned 556,247 shares in the company, valued at $16,320,286.98. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Bredt sold 8,500 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $29.02, for a total transaction of $246,670.00. Following the sale, the insider directly owned 387,075 shares of the company’s stock, valued at $11,232,916.50. This represents a 2.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 69,669 shares of company stock worth $1,999,877. Insiders own 13.57% of the company’s stock.

Institutional Investors Weigh In On Rapport Therapeutics

Several large investors have recently bought and sold shares of the company. Baker BROS. Advisors LP lifted its position in shares of Rapport Therapeutics by 181.2% in the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after acquiring an additional 997,000 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $28,215,000. Polar Capital Holdings Plc purchased a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $27,887,000. Capital International Investors raised its stake in Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock valued at $101,055,000 after purchasing an additional 800,000 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Rapport Therapeutics by 265.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company’s stock valued at $26,500,000 after purchasing an additional 648,378 shares during the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.